<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The authors evaluated the efficacy of <z:chebi fb="0" ids="8871">risperidone</z:chebi> in reducing <z:e sem="disease" ids="C0033975,C0459435" disease_type="Mental or Behavioral Dysfunction;Finding" abbrv="">psychotic</z:e> and aggressive symptoms in a subgroup of patients who fulfilled operationalized criteria for <z:hpo ids='HP_0000709'>psychosis</z:hpo> of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Authors conducted a subgroup analysis of patients in the <z:chebi fb="0" ids="8871">risperidone</z:chebi> database arising from a previous double-blind, randomized, placebo-controlled study </plain></SENT>
<SENT sid="2" pm="."><plain>In the primary study, patients age 55 or older, with a <z:chebi fb="4" ids="38624">DSM</z:chebi>-IV diagnosis of <z:hpo ids='HP_0002511'>Alzheimer disease</z:hpo> and/or vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> were randomized to placebo or 0.5 mg, 1.0 mg, or 2.0 mg/day of <z:chebi fb="0" ids="8871">risperidone</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>For this analysis, patients were selected who fulfilled operationalized criteria for <z:hpo ids='HP_0000709'>psychosis</z:hpo> of <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>These criteria were then validated </plain></SENT>
<SENT sid="5" pm="."><plain>The primary outcome measures were the newly developed <z:hpo ids='HP_0000709'>Psychosis</z:hpo> and <z:hpo ids='HP_0000718'>Aggression</z:hpo> Severity Indices, derived from Parts 1 and 2 of the BEHAVE-AD rating scale </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: At Week 12 and endpoint, patients with <z:hpo ids='HP_0000709'>psychosis</z:hpo> of <z:hpo ids='HP_0000726'>dementia</z:hpo> receiving 1 mg or 2 mg/day of <z:chebi fb="0" ids="8871">risperidone</z:chebi> showed significantly more improvement on the <z:hpo ids='HP_0000709'>Psychosis</z:hpo> Severity and <z:hpo ids='HP_0000718'>Aggressiveness</z:hpo> Severity Indices than those receiving placebo </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The construct of <z:hpo ids='HP_0000709'>psychosis</z:hpo> of <z:hpo ids='HP_0000726'>dementia</z:hpo> was validated, and the severity of both <z:hpo ids='HP_0000709'>psychosis</z:hpo> and <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> was reduced with <z:chebi fb="0" ids="8871">risperidone</z:chebi> treatment in a robust and dose-related way, with a continuing response over the 12-week trial period </plain></SENT>
</text></document>